DOUGLAS RICHARD

Director Douglas Richard buys 70.0K shares of ALDX at $1.40; holds 195.0K post-trade. Stock down 73.1% from 52-week high.

Director Douglas Richard purchased 70,000 shares at $1.40 on 2026-03-19, increasing his position from 125,000 to 195,000 shares (+56.0% increase in holdings). The transaction occurred while Aldeyra Therapeutics reported a net loss of $7.7M over its most recent full fiscal year, indicating the company remains unprofitable. The stock has declined 73.1% from its 52-week high of $6.72 and is now trading at $1.81, representing a 30-day decline of 63.9%. Richard's purchase history shows only 1 prior buy across all his open-market activity, making this accumulation the second documented discretionary purchase in his insider trading record. The combination of significant share count addition, sustained price deterioration, and the company's negative profitability creates a signal worth monitoring for investor patterns at this stage of the company's performance cycle.

Director Douglas Richard bought 80,000 shares of MXCT at $1.39 on 2025-08-13 in cluster-buy pattern while stock down -72.9% from 52-week high.

Douglas Richard, a director at MaxCyte, purchased 80,000 shares at $1.39, increasing his holdings from 150,577 to 230,577 shares (+53.1%). The transaction occurs as the stock trades -72.9% below its 52-week high of $5.10 and has declined -38.4% over the past 30 days. Notably, this purchase is part of a broader pattern: four other insiders also bought within the past 14 days, suggesting coordinated interest at depressed price levels. However, the company remains unprofitable with net income of $-12,357,000.00 in the latest quarter and full-year net income negative, alongside declining annual revenue growth of -6.4%, creating a structural tension between insider accumulation and deteriorating fundamentals that warrants close investor scrutiny.